Trial Profile
To determine association of circulating aberrations of androgen receptor as well as serum chromogranin A (CgA) in outcomes of Castration resistant prostatic cancer patients treated with Abiraterone and Enzalutamide
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 27 Mar 2017
Price :
$35
*
At a glance
- Drugs Abiraterone (Primary) ; Enzalutamide (Primary) ; Prednisone
- Indications Prostate cancer
- Focus Therapeutic Use
- 27 Mar 2017 New trial record
- 18 Feb 2017 Results presented at the 2017 Genitourinary Cancers Symposium